LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | XMD11-85h | 0.37 | uM | LJP6 | 72 | hr | 1235 | 3599 | 4056 | 0.8884 | 0.8660 |
| MCF7 | XMD11-85h | 1.11 | uM | LJP6 | 72 | hr | 1235 | 3439 | 4056 | 0.8476 | 0.8151 |
| MCF7 | XMD11-85h | 3.33 | uM | LJP6 | 72 | hr | 1235 | 3133 | 4056 | 0.7723 | 0.7200 |
| MCF7 | XMD11-85h | 10 | uM | LJP6 | 72 | hr | 1235 | 1983 | 4056 | 0.4883 | 0.3156 |
| MCF7 | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 1235 | 1716 | 4267 | 0.4022 | 0.2014 |
| MCF7 | XMD16-144 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 1640 | 4267 | 0.3844 | 0.1715 |
| MCF7 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1235 | 1788 | 4267 | 0.4193 | 0.2299 |
| MCF7 | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 1787 | 4267 | 0.4189 | 0.2291 |
| MCF7 | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1764 | 4267 | 0.4135 | 0.2203 |
| MCF7 | XMD16-144 | 10 | uM | LJP5 | 72 | hr | 1235 | 732 | 4267 | 0.1712 | -0.2564 |
| MCF7 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 3468 | 4267 | 0.8130 | 0.7814 |
| MCF7 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 3604 | 4267 | 0.8453 | 0.8206 |
| MCF7 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4342 | 4267 | 1.0177 | 1.0198 |
| MCF7 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4396 | 4267 | 1.0296 | 1.0322 |
| MCF7 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4324 | 4267 | 1.0121 | 1.0114 |
| MCF7 | Erlotinib | 10 | uM | LJP5 | 72 | hr | 1235 | 4268 | 4267 | 1.0002 | 1.0002 |
| MCF7 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 4620 | 4056 | 1.1386 | 1.1569 |
| MCF7 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4513 | 4056 | 1.1132 | 1.1287 |
| MCF7 | Gefitinib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 4531 | 4056 | 1.1178 | 1.1318 |
| MCF7 | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 4574 | 4056 | 1.1283 | 1.1455 |
| MCF7 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4423 | 4056 | 1.0911 | 1.1044 |
| MCF7 | Gefitinib | 10 | uM | LJP6 | 72 | hr | 1235 | 3444 | 4056 | 0.8493 | 0.8164 |
| MCF7 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4461 | 4267 | 1.0455 | 1.0503 |
| MCF7 | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4440 | 4267 | 1.0408 | 1.0454 |
| MCF7 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4256 | 4267 | 0.9961 | 0.9934 |